Loading patent…
AssigneeBristol-Meyers Squibb Company
InventorsRenzo Mauro Canetta, Elizabeth Eisenhauer, Marcel Rozencweig
Estimating the term…
Taxol dosages of about 135 mg/m.sup.2 or greater are administered via infusions of less than 6 hours duration; the method makes it possible to provide taxol infusions on an out-patient basis to patients who do not otherwise require hospitalization. In a preferred embodiment, about 135 mg/m.sup.2 of taxol in a cremaphor emulsion is infused over a 3 hour duration, following patient pretreatment with steroids, antihistamines, and H.sub.2 -receptor antagonists sufficient to prevent fatal anaphylactic-like reactions, and preferably sufficient to reduce the occurrence of severe anaphylactic-like reactions in greater than 90% of patients treated. In an alternative embodiment, between 135 mg/m.sup.2 and about 175 mg/m.sup.2 of taxol is provided in a 3-hour infusion, following pretreatment to minimize hypersensitivity responses. A method for rechallenging patients with taxol after episodes of acute hypersensitivity reactions is also disclosed, thus enabling patients to continue taxol therapy who would otherwise be deprived of treatment.
A method for treating a patient suffering from a taxol-sensitive tumor comprising
A method for treating a patient suffering from a taxol-sensitive tumor comprising
A method for treating a patient suffering from a taxol-sensitive ovarian tumor comprising
A method for treating a patient suffering from a taxol-sensitive ovarian tumor comprising
A method for treating a cancer patient to effect regression of a taxol-sensitive tumor, said method being associated with reduced hematologic toxicity, said method comprising:
A method for treating a cancer patient to effect regression of a taxol-sensitive tumor, said method being associated with reduced hematologic toxicity, said method comprising:
Dependencies are inferred from the claim text.